Search Results - "McKone, E.F"

EPS5.9 The prevalence of obesity in Irish adults with cystic fibrosis: a registry study by Dudina, A.L, Fletcher, G, Gallagher, C.G, McKone, E.F

Get full text

274 The relationship between isokinetic quadriceps strength and disease severity in cystic fibrosis by Reilly, C.M, Buckley, R, Kelly, S, McKone, E.F, Gallagher, C.G

Get full text

114 Treatment of Mycobacterium abscessus in adult cystic fibrosis patients by Connolly, A, Moran, M, Keane, C, McKone, E.F, Gallagher, C.G

Get full text

74 Ivacaftor treatment activates circulating neutrophils in R117H patients: potential for a CFTR independent mechanism by Hardisty, G, Law, S, Carter, S.C, Grogan, B, Singh, P.K, McKone, E.F, Gray, R

Get full text

WS04.1 The effect of Orkambi® on exercise capacity and muscle strength by Buckley, R, Reilly, C.M, Kelly, S, Ward, E, Gallagher, C.G, McKone, E.F

Get full text

EPS5.6 Temporal trends in key outcome measures in cystic fibrosis patients treated with ivacaftor: real-world data from the Irish CF registry by Kirwan, L, Fletcher, G, Harrington, M, Zhou, S, Jeleniewska, P, McKone, E.F, Jackson, A.D

Get full text

Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T by Carter, S, Kelly, S, Caples, E, Grogan, B, Doyle, J, Gallagher, C.G, McKone, E.F

“…Abstract Ivacaftor is a novel CFTR potentiator that increases CFTR activity and improves clinical outcomes in cystic fibrosis (CF) patients with at least one…”
Get full text

EPS5.2 Genetic epidemiology of CFTR nonsense mutations across Europe by McKone, E.F, Jackson, A, Zolin, A, De Boeck, K, van Rens, J, Ariti, C, Keogh, R, Naehrlich, L

Get full text

47 Effects of lumacaftor/ivacaftor in patients homozygous for F508del mutation with very advanced lung disease by Carter, S.C, Kearns, S, Grogan, B, Hisert, K.B, Cooke, G, Singh, P.K, Gallagher, C.G, McKone, E.F

Get full text

WS11.3 Cystic fibrosis survival and socioeconomic status across Europe by McKone, E.F, Ariti, C, Jackson, A, Zolin, A, Carr, S.B, van Rens, J, Colomb, V, Lemonnier, L, Keogh, R, Naehrlich, L

Get full text

54 Relationship between rate of percent predicted FEV1 (ppFEV1 ) decline and baseline and acute change in ppFEV1 in patients (pts) with cystic fibrosis (CF) treated with lumacaftor/ivacaftor (LUM/IVA) by Konstan, M.W, McKone, E.F, Moss, R.B, Lubarsky, B, Rubin, J, Millar, S.J, Pasta, D.J, Mayer-Hamblett, N, Goss, C.H, Morgan, W, Sawicki, G.S

Get full text

WS13.6 GLPG1837 in subjects with cystic fibrosis (CF) and the G551D mutation: results from a phase II study (SAPHIRA1) by Davies, J, Bell, S.C, Van Koningsbruggen-Rietschel, S, McKone, E.F, Macgregor, G, Drevinek, P, Conrath, K, de Kock, H, Gesson, C, Kanters, D, Van de Steen, O

Get full text

WS7.6 UK and Ireland review of ivacaftor in severe CF: Impact on lung function and weight by Barry, P.J, Plant, B.J, Nair, A, Simmonds, N.J, Bicknell, S, Shafi, N.T, Bell, N.J, Daniels, T, Felton, I, Gunaratnam, C, McKone, E.F, Jones, A.M, Horsley, A.R

Get full text

54 UK and Ireland review of ivacaftor in severe CF: Impact on hospitalisations and antibiotic use by Barry, P.J, Plant, B.J, Simmonds, N.J, Bicknell, S, Shafi, N.T, Bell, N.J, Daniels, T, Felton, I, Gunaratnam, C, McKone, E.F, Jones, A.M, Horsley, A.R

Get full text

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele by Middleton, Peter G, Mall, Marcus A, Dřevínek, Pavel, Lands, Larry C, McKone, Edward F, Polineni, Deepika, Ramsey, Bonnie W, Taylor-Cousar, Jennifer L, Tullis, Elizabeth, Vermeulen, François, Marigowda, Gautham, McKee, Charlotte M, Moskowitz, Samuel M, Nair, Nitin, Savage, Jessica, Simard, Christopher, Tian, Simon, Waltz, David, Xuan, Fengjuan, Rowe, Steven M, Jain, Raksha

“…Triple treatment with elexacaftor, tezacaftor, and ivacaftor in patients with cystic fibrosis who had one Phe508del allele and a minimal-function mutation…”
Get full text

The role of supplemental oxygen during submaximal exercise in patients with cystic fibrosis by McKone, E.F, Barry, S.C, FitzGerald, M.X, Gallagher, C.G

“…Repeated bouts of submaximal exercise are an important part of most pulmonary rehabilitation programmes. Patients with moderate-to-severe cystic fibrosis (CF)…”
Get full text

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR by Wainwright, Claire E, Elborn, J. Stuart, Ramsey, Bonnie W, Marigowda, Gautham, Huang, Xiaohong, Cipolli, Marco, Colombo, Carla, Davies, Jane C, De Boeck, Kris, Flume, Patrick A, Konstan, Michael W, McColley, Susanna A, McCoy, Karen, McKone, Edward F, Munck, Anne, Ratjen, Felix, Rowe, Steven M, Waltz, David, Boyle, Michael P

“…This study identified a new combination therapy for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. Treatment with ivacaftor, a CFTR…”
Get full text

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis by Goss, C.H, McKone, E.F, Mathews, D, Kerr, D, Wanger, J.S, Millard, S.P

“…Abstract Background Centralized spirometry may significantly improve quality of spirometry and reduce variability of this outcome measure in clinical trials in…”
Get full text

Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes by Barry, Peter J, Mall, Marcus A, Álvarez, Antonio, Colombo, Carla, de Winter-de Groot, Karin M, Fajac, Isabelle, McBennett, Kimberly A, McKone, Edward F, Ramsey, Bonnie W, Sutharsan, Sivagurunathan, Taylor-Cousar, Jennifer L, Tullis, Elizabeth, Ahluwalia, Neil, Jun, Lucy S, Moskowitz, Samuel M, Prieto-Centurion, Valentin, Tian, Simon, Waltz, David, Xuan, Fengjuan, Zhang, Yaohua, Rowe, Steven M, Polineni, Deepika

“…Elexacaftor–ivacaftor–tezacaftor therapy is efficacious in cystic fibrosis among patients with at least one copy of the Phe508del allele. In this trial…”
Get full text

Lung Transplant Referral Consensus Guidelines for Individuals with Cystic Fibrosis: An Opportunity for Partnerships between CF and Lung Transplant Centers by Ramos, K.J., Smith, P.J., McKone, E.F., Pilewski, J.M., Lucy, A., Hempstead, S.E., Tallarico, E., Faro, A., Rosenbluth, D.B., Gray, A.L., Dunitz, J.M.

“…Nearly 40% of individuals with cystic fibrosis (CF) and decreased FEV1 die without lung transplantation (LTx) in the United States, with an annual mortality…”
Get full text